10x Genomics (NASDAQ:TXG – Get Free Report) CEO Serge Saxonov sold 31,000 shares of 10x Genomics stock in a transaction that occurred on Tuesday, November 10th. The shares were sold at an average price of $62.90, for a total value of $1,949,900.00. Following the transaction, the chief executive officer directly owned 1,019,249 shares in the company, valued at approximately $64,110,762.10. The trade was a 2.95% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Serge Saxonov also recently made the following trade(s):
- On Tuesday, September 22nd, Serge Saxonov sold 25,000 shares of 10x Genomics stock. The stock was sold at an average price of $81.22, for a total value of $2,030,500.00.
- On Wednesday, August 26th, Serge Saxonov sold 10,486 shares of 10x Genomics stock. The shares were sold at an average price of $63.69, for a total value of $667,853.34.
- On Monday, August 24th, Serge Saxonov sold 18,545 shares of 10x Genomics stock. The shares were sold at an average price of $63.02, for a total transaction of $1,168,705.90.
10x Genomics Stock Performance
Shares of 10x Genomics stock traded down $0.91 during mid-day trading on Friday, hitting $58.19. 2,122,971 shares of the stock were exchanged, compared to its average volume of 3,020,785. 10x Genomics has a 12 month low of $15.12 and a 12 month high of $102.81. The company has a 50-day simple moving average of $74.02 and a 200 day simple moving average of $42.38. The company has a market capitalization of $7.58 billion, a P/E ratio of -111.90 and a beta of 2.03.
10x Genomics (NASDAQ:TXG – Get Free Report) last released its earnings results on Thursday, November 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.12. The company had revenue of $150.67 million during the quarter, compared to analyst estimates of $147.96 million. 10x Genomics had a negative return on equity of 8.19% and a negative net margin of 10.84%. 10x Genomics’s quarterly revenue was up 1.1% on a year-over-year basis. During the same period in the prior year, the company posted ($0.22) earnings per share. Analysts predict that 10x Genomics will post -0.74 EPS for the current year.
Wall Street Analyst Weigh In
Several research analysts have weighed in on the company. Stifel Nicolaus boosted their price objective on 10x Genomics from $50.00 to $68.00 and gave the stock a “buy” rating in a research report on Friday, November 6th. TD Cowen raised their target price on 10x Genomics from $47.00 to $70.00 and gave the company a “hold” rating in a research report on Tuesday, October 13th. Morgan Stanley lifted their target price on 10x Genomics from $40.00 to $70.00 and gave the stock an “equal weight” rating in a research note on Monday, October 12th. Leerink Partners boosted their price target on shares of 10x Genomics from $40.00 to $90.00 and gave the stock a “market perform” rating in a report on Tuesday, September 29th. Finally, Barclays cut their price target on shares of 10x Genomics from $110.00 to $70.00 and set an “overweight” rating on the stock in a report on Monday. Five research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $68.40.
Institutional Investors Weigh In On 10x Genomics
Large investors have recently modified their holdings of the stock. Bleakley Financial Group LLC purchased a new position in 10x Genomics in the third quarter valued at approximately $2,395,000. Essex Financial Services Inc. purchased a new stake in 10x Genomics in the third quarter worth $393,000. First Trust Advisors LP increased its position in 10x Genomics by 8.8% in the third quarter. First Trust Advisors LP now owns 451,226 shares of the company’s stock worth $40,773,000 after buying an additional 36,332 shares during the last quarter. Advisors Asset Management Inc. purchased a new stake in 10x Genomics in the third quarter worth $210,000. Finally, USS Investment Management Ltd purchased a new stake in 10x Genomics in the third quarter worth $11,716,000. Hedge funds and other institutional investors own 84.68% of the company’s stock.
About 10x Genomics
10x Genomics, Inc. develops technology for studying biological systems at single-cell and spatial resolution. Its instruments, consumables and software help researchers analyze gene expression and other features of cells while preserving information about their location within tissue. The company’s product platforms include Chromium for single-cell analysis, Visium for spatial gene-expression analysis and Xenium for in situ analysis of gene activity within tissue samples. Its tools are used in areas such as immunology, neuroscience, cancer research and drug discovery.
Further Reading
- Five stocks we like better than 10x Genomics
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 10x Genomics and related companies with MarketBeat.com's FREE daily email newsletter.
